Gilead Sciences Inc (GILD)
Return on total capital
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | 1,668,000 | 1,157,000 | 2,514,000 | 2,042,000 | 7,803,000 | 8,156,000 | 8,266,000 | 8,194,000 | 6,750,000 | 5,489,000 | 6,516,000 | 6,844,000 | 9,279,000 | 10,363,000 | 7,736,000 | 2,931,000 | 2,654,000 | 2,717,000 | 405,000 | 5,795,000 |
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 19,330,000 | 18,474,000 | 18,281,000 | 17,539,000 | 22,749,000 | 22,242,000 | 21,094,000 | 20,939,000 | 21,209,000 | 21,057,000 | 20,236,000 | 19,915,000 | 21,064,000 | 21,471,000 | 19,710,000 | 18,964,000 | 18,221,000 | 17,471,000 | 18,142,000 | 22,179,000 |
| Return on total capital | 8.63% | 6.26% | 13.75% | 11.64% | 34.30% | 36.67% | 39.19% | 39.13% | 31.83% | 26.07% | 32.20% | 34.37% | 44.05% | 48.27% | 39.25% | 15.46% | 14.57% | 15.55% | 2.23% | 26.13% |
December 31, 2024 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $1,668,000K ÷ ($—K + $19,330,000K)
= 8.63%
Gilead Sciences Inc's return on total capital has displayed fluctuations over the specified periods. The ratio ranged from a low of 2.23% in June 2020 to a peak of 48.27% in September 2021, showcasing significant variability in the company's ability to generate returns from its total capital. There was a notable decline in the return on total capital in the second half of 2024, with values falling to 6.26% in September and 8.63% in December. This downward trend indicates a potential reduction in the efficiency of utilizing total capital to generate profits during that period. Overall, the return on total capital for Gilead Sciences Inc has exhibited both strong performance and periods of relative weakness, reflecting the company's changing financial performance dynamics.
Peer comparison
Dec 31, 2024